EW:NYE-Edwards Lifesciences Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 78.1

Change

-0.12 (-0.15)%

Market Cap

USD 18.35B

Volume

2.62M

Analyst Target

USD 86.75
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Edwards Lifesciences Corp technologies that treat structural heart disease and critically ill patients. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-02 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.14 (+0.10%)

USD 234.53B
MDT Medtronic PLC

+1.80 (+2.15%)

USD 110.86B
STE STERIS plc

+1.25 (+0.52%)

USD 24.09B
ZBH Zimmer Biomet Holdings Inc

+0.74 (+0.81%)

USD 18.24B
SNN Smith & Nephew SNATS Inc

-0.03 (-0.10%)

USD 12.64B
PEN Penumbra Inc

+1.20 (+0.47%)

USD 10.40B
GMED Globus Medical

+0.74 (+1.26%)

USD 7.98B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 7.14B
BIO Bio-Rad Laboratories Inc

+4.01 (+1.85%)

USD 6.69B
GKOS Glaukos Corp

-0.30 (-0.32%)

USD 5.49B

ETFs Containing EW

CYBG:LSE VanEck Bionic Engineering.. 10.75 % 0.00 %

+0.17 (+1.07%)

N/A
CIB0:XETRA VanEck Bionic Engineering.. 10.32 % 0.00 %

+0.28 (+1.07%)

N/A
UMDV:SW iShares US Medical Device.. 4.94 % 0.00 %

N/A

N/A
5PAH:XETRA Global X S&P 500® Annual.. 4.48 % 0.00 %

+0.16 (+1.07%)

N/A
WHCS:SW 2.80 % 0.00 %

N/A

N/A
XHE SPDR® S&P Health Care Eq.. 1.97 % 0.35 %

+1.36 (+1.07%)

USD 0.17B
RSPH Invesco S&P 500 Equal Wei.. 1.90 % 0.00 %

+0.19 (+1.07%)

USD 0.75B
SMTV:LSE VanEck Morningstar US SMI.. 1.46 % 0.00 %

+24.80 (+1.07%)

USD 0.02B
WELE:XETRA Amundi S&P 500 Equal Weig.. 0.59 % 0.00 %

+0.19 (+1.07%)

N/A
HECO SPDR Galaxy Hedged Digita.. 0.00 % 0.95 %

+0.84 (+1.07%)

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.27 (+1.07%)

N/A
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

+0.22 (+1.07%)

USD 0.17B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

-0.11 (1.07%)

CAD 0.01B
INAU 0.00 % 0.00 %

N/A

N/A
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+4.75 (+1.07%)

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

+0.06 (+1.07%)

N/A
XSDX:LSE Xtrackers ShortDAX Daily .. 0.00 % 0.00 %

-6.60 (1.07%)

USD 0.19B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

+0.12 (+1.07%)

USD 2.84M
AGNG Global X Aging Population.. 0.00 % 0.00 %

-0.11 (1.07%)

USD 0.06B
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

+0.23 (+1.07%)

N/A
CBUF:F iShares V Public Limited .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.50% 76% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.50% 76% C+ 75% C
Trailing 12 Months  
Capital Gain -11.11% 55% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.11% 55% F 18% F
Trailing 5 Years  
Capital Gain 4.51% 54% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.51% 54% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -3.02% 48% F 23% F
Dividend Return -3.02% 45% F 13% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.07% 58% F 30% F
Risk Adjusted Return -10.04% 42% F 19% F
Market Capitalization 18.35B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 35.30 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.